Cooper Companies (NASDAQ:COO) Trading Down 3.2% – Here’s What Happened

The Cooper Companies, Inc. (NASDAQ:COO) shares fell 3.2% during mid-day trading on Thursday . The company traded as low as $53.15 and last traded at $52.8750. 419,036 shares changed hands during mid-day trading, a decline of 83% from the average daily volume of 2,505,022 shares. The stock had previously closed at $54.61.

Cooper Companies News Roundup

Here are the key news stories impacting Cooper Companies this week:

• Positive Sentiment: Cooper Companies insiders showed confidence in the valuation through substantial purchases. Directors Paul Keel, Lawrence Kurzius and Walter Rosebrough Jr. collectively bought approximately $1.33 million of COO shares at prices around $53–$54 per share. These purchases could provide some support by signaling that insiders view the decline as excessive. Paul Keel insider purchase
• Positive Sentiment: The company’s $3 billion share-repurchase authorization, representing authorization to buy back up to roughly 22.7% of outstanding shares, may help support the stock and reflects management’s view that the shares are undervalued. However, buybacks may be less effective while earnings expectations remain under pressure.
• Neutral Sentiment: Multiple law firms, including Pomerantz, Bragar Eagel & Squire, Levi & Korsinsky and Kirby McInerney, have announced investigations into potential securities-law claims related to Cooper’s disclosures and the post-earnings selloff. These announcements add headline and potential litigation risk, but they do not establish wrongdoing. Pomerantz investigation
• Negative Sentiment: Third-quarter revenue of approximately $1.07 billion missed the $1.10 billion consensus estimate, despite adjusted EPS of $1.15 exceeding the $1.12 estimate. Investors focused on U.S. channel inventory reductions, which suggest distributors are destocking and could weigh on near-term sales. HBSS inventory report
• Negative Sentiment: Cooper lowered fiscal 2026 revenue guidance to approximately $4.23–$4.25 billion and adjusted EPS guidance to $4.51–$4.55, reflecting softer contact-lens demand, particularly at CooperVision. Analysts have also reduced the consensus price target to about $72.27, reinforcing concerns about slower growth.

Analysts Set New Price Targets

COO has been the topic of several recent analyst reports. Mizuho set a $75.00 target price on Cooper Companies and gave the stock an “outperform” rating in a report on Thursday, September 10th. BNP Paribas Exane dropped their price target on shares of Cooper Companies from $95.00 to $92.00 and set an “outperform” rating for the company in a research note on Monday, June 8th. William Blair cut Cooper Companies from an “outperform” rating to a “market perform” rating in a report on Thursday, September 10th. Zacks Research cut shares of Cooper Companies from a “hold” rating to a “strong sell” rating in a research report on Friday, September 11th. Finally, Wells Fargo & Company set a $61.00 target price on shares of Cooper Companies and gave the stock an “equal weight” rating in a report on Thursday, September 10th. Five equities research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and three have issued a Sell rating to the company. Based on data from MarketBeat.com, Cooper Companies currently has a consensus rating of “Hold” and a consensus price target of $71.47.

Cooper Companies Stock Performance

The stock’s 50-day moving average price is $70.58 and its 200 day moving average price is $68.98. The firm has a market cap of $10.16 billion, a P/E ratio of 18.22, a price-to-earnings-growth ratio of 2.17 and a beta of 0.82. The company has a debt-to-equity ratio of 0.23, a current ratio of 1.22 and a quick ratio of 0.73.

Cooper Companies (NASDAQ:COO) last issued its quarterly earnings results on Wednesday, September 9th. The medical device company reported $1.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.12 by $0.03. Cooper Companies had a net margin of 13.46% and a return on equity of 10.90%. The firm had revenue of $1.07 billion for the quarter, compared to analyst estimates of $1.10 billion. During the same period in the previous year, the business earned $0.49 EPS. The company’s revenue was up .5% compared to the same quarter last year. Cooper Companies has set its Q4 2026 guidance at 1.050-1.090 EPS and its FY 2026 guidance at 4.510-4.550 EPS. As a group, equities analysts predict that The Cooper Companies, Inc. will post 4.53 EPS for the current year.

Cooper Companies announced that its board has initiated a stock repurchase program on Wednesday, September 9th that authorizes the company to buyback $3.00 billion in outstanding shares. This buyback authorization authorizes the medical device company to buy up to 22.7% of its stock through open market purchases. Stock buyback programs are typically a sign that the company’s board believes its stock is undervalued.

Insider Transactions at Cooper Companies

In other news, Director Walter M. Rosebrough, Jr. purchased 3,000 shares of the company’s stock in a transaction on Monday, September 14th. The shares were purchased at an average cost of $54.29 per share, with a total value of $162,870.00. Following the completion of the transaction, the director owned 20,000 shares of the company’s stock, valued at $1,085,800. The trade was a 17.65% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Lawrence Kurzius purchased 10,000 shares of the business’s stock in a transaction on Monday, September 14th. The stock was purchased at an average price of $53.91 per share, with a total value of $539,100.00. Following the purchase, the director owned 21,099 shares of the company’s stock, valued at approximately $1,137,447.09. The trade was a 90.10% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders have purchased a total of 24,701 shares of company stock worth $1,330,739 in the last 90 days. Corporate insiders own 2.08% of the company’s stock.

Institutional Investors Weigh In On Cooper Companies

Several hedge funds have recently bought and sold shares of COO. Root Financial Partners LLC lifted its position in shares of Cooper Companies by 104.5% in the fourth quarter. Root Financial Partners LLC now owns 317 shares of the medical device company’s stock valued at $26,000 after buying an additional 162 shares during the last quarter. Avalon Trust Co bought a new stake in Cooper Companies in the 2nd quarter valued at $25,000. SJS Investment Consulting Inc. raised its stake in Cooper Companies by 107.5% in the 1st quarter. SJS Investment Consulting Inc. now owns 361 shares of the medical device company’s stock valued at $26,000 after acquiring an additional 187 shares during the period. Elevation Wealth Partners LLC lifted its holdings in Cooper Companies by 1,136.4% during the 2nd quarter. Elevation Wealth Partners LLC now owns 408 shares of the medical device company’s stock valued at $29,000 after purchasing an additional 375 shares during the last quarter. Finally, Continuum Advisory LLC acquired a new stake in Cooper Companies during the 2nd quarter valued at $30,000. 24.39% of the stock is currently owned by institutional investors and hedge funds.

Cooper Companies Company Profile

Cooper Companies, Inc is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company develops, manufactures and markets products through two primary business segments: CooperVision and CooperSurgical.

CooperVision specializes in contact lenses, including daily disposable, toric, multifocal, multifocal toric, specialty and myopia-management lenses. Its products are designed to address a range of vision-correction needs, including astigmatism, presbyopia and irregular corneas.